Integer's Q4 sales growth tops estimates on cardio, vascular segment growth

Overview

• Medical device maker's Q4 2025 sales rose 5%, beating analyst expectations

• Adjusted EPS for Q4 2025 beat analyst expectations

• Company repurchased 698,356 shares for $50 mln, plans accelerated share repurchase

Outlook

• Integer maintains 2026 sales growth midpoint from October outlook

• Integer anticipates 2026 adjusted EPS growth at high end of October outlook

• Company expects 200bps above-market organic sales growth in 2027

Result Drivers

• CARDIO & VASCULAR GROWTH - Sales increased 11% in Q4 2025, driven by acquisitions and strong demand in Neurovascular

• NEUROMODULATION DECLINE - Cardiac Rhythm Management & Neuromodulation sales decreased 2% in Q4 2025, due to lower demand from select emerging customers

• OTHER MARKETS DECLINE - Sales decreased 13% in Q4 2025, impacted by the exit from Portable Medical

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Integer Holdings Corp is $87.00, about 0.6% above its February 18 closing price of $86.48

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nGNXbfKTzX

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.